The treatment of hyperlipidemia in patients infected with HIV is discussed. Hyperlipidemia is common in HIV-infected patients receiving antiretroviral therapy, especially protease inhibitors and ...

Research led by Baylor College of Medicine has shown that a new therapy significantly reduces triglyceride levels in individuals with mixed hyperlipidemia – elevations of triglycerides and cholesterol ...

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced results from the Phase 2b double blind, randomized MUIR study of investigational plozasiran (formerly ...

New drugs that lower cholesterol and treat hyperlipidemia are preparing to enter the market. According to The New York Times (NYT) and The Wall Street Journal (WSJ) on the 9th, U.S. pharmaceutical ...

In a breakthrough for cardiovascular medicine, researchers have harnessed artificial intelligence to discover unexpected lipid-lowering effects in existing FDA-approved drugs. The study, published in ...

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia - ARO-DIMER-PA is the first clinical ...

Cholesterol is a type of fat that helps the human body make cell membranes, hormones, and vitamin D. The recommended total limit of cholesterol is 200mg/dL, with HDL (“good” cholesterol) being above ...

Clinical outcomes for low-income patients with early-onset breast cancer: An analysis of the National Inpatient Sample. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This ...

NCEP guidelines recommend monitoring LDL cholesterol levels four to six weeks after the start of lipid-lowering therapy and then at three months. [9] Although the optimum follow-up times for an ...

- ARO-DIMER-PA is the first clinical candidate designed to silence the expression of two genes with a single RNAi molecule - In preclinical studies, ARO-DIMER-PA potently lowered serum PCSK9 and APOC3 ...

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced results from the Phase 2b double blind, randomized ARCHES-2 study of investigational zodasiran ...